LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Lista de Ações・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Fechado

SetorSaúde

433.1 -0.04

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

432.05

Máximo

438.16

Indicadores-chave
By Trading Economics
Rendimento	-160M 1B
Vendas	-240M 3B
P/E Médio do Setor	25.91 49.701
EPS	4.47
Margem de lucro	34.531
Funcionários	6,400
EBITDA	-215M 1.1B

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+29.84% upside

Dividendos
By Dow Jones
Próximos Ganhos	3 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	2.4B 111B
Abertura anterior	433.14
Fecho anterior	433.1

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

428.545 / 498.65 Suporte e Resistência

Vertex Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de mai. de 2026, 20:57 UTC

Ganhos

Vertex Pharmaceuticals Posts Higher 1Q Profit

12 de fev. de 2026, 21:47 UTC

Ganhos

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

3 de nov. de 2025, 21:44 UTC

Ganhos

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

5 de ago. de 2025, 00:05 UTC

Ações em Alta

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

4 de ago. de 2025, 21:21 UTC

Ganhos

Grandes Movimentos do Mercado

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 de ago. de 2025, 20:45 UTC

Ganhos

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 de mai. de 2026, 20:02 UTC

Ganhos

Vertex Pharmaceuticals Reiterates 2026 Guidance

4 de mai. de 2026, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 1Q Net $1.03B >VRTX

4 de mai. de 2026, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 1Q Rev $2.99B >VRTX

4 de mai. de 2026, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 1Q Adj EPS $4.47 >VRTX

4 de mai. de 2026, 20:01 UTC

Ganhos

Vertex Pharmaceuticals 1Q EPS $4.02 >VRTX

12 de fev. de 2026, 21:13 UTC

Ganhos

Vertex Pharmaceuticals Guidance Includes Immaterial Cost Impact From Tariffs in 2026 >VRTX

12 de fev. de 2026, 21:13 UTC

Ganhos

Vertex Pharmaceuticals Sees FY26 Rev $12.95B-$13.1B >VRTX

12 de fev. de 2026, 21:01 UTC

Ganhos

Vertex Pharmaceuticals 4Q Rev $3.19B >VRTX

12 de fev. de 2026, 21:01 UTC

Ganhos

Vertex Pharmaceuticals 4Q Net $1.19B >VRTX

12 de fev. de 2026, 21:01 UTC

Ganhos

Vertex Pharmaceuticals 4Q EPS $4.65 >VRTX

12 de fev. de 2026, 21:01 UTC

Ganhos

Vertex Pharmaceuticals 4Q Adj EPS $5.03 >VRTX

3 de nov. de 2025, 21:05 UTC

Ganhos

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3 de nov. de 2025, 21:02 UTC

Ganhos

Vertex Pharmaceuticals 3Q EPS $4.20 >VRTX

3 de nov. de 2025, 21:02 UTC

Ganhos

Vertex Pharmaceuticals 3Q Adj EPS $4.80 >VRTX

3 de nov. de 2025, 21:02 UTC

Ganhos

Vertex Pharmaceuticals 3Q Net $1.08B >VRTX

3 de nov. de 2025, 21:02 UTC

Ganhos

Vertex Pharmaceuticals 3Q Rev $3.08B >VRTX

5 de ago. de 2025, 20:44 UTC

Ganhos

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 de ago. de 2025, 18:17 UTC

Ganhos

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 de ago. de 2025, 15:25 UTC

Ganhos

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 de ago. de 2025, 14:12 UTC

Ganhos

Vertex Stock Tumbles After Strong Earnings. What's Spooking Investors. -- Barrons.com

5 de ago. de 2025, 11:27 UTC

Ganhos

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 de ago. de 2025, 10:55 UTC

Ganhos

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 de ago. de 2025, 10:36 UTC

Ganhos

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 de ago. de 2025, 10:18 UTC

Ganhos

Vertex Stock Tumbles 15% After Strong Earnings. What's Spooking Investors. -- Barrons.com

Comparação entre Pares

Variação de preço

Vertex Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

29.84% parte superior

Previsão para 12 meses

Média 562.9 USD 29.84%

Máximo 641 USD

Mínimo 436 USD

Com base em 24 analistas de Wall Street que oferecem metas de preço de 12 meses para Vertex Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

24 ratings

Comprar

Manter

Vender

Com base em 24 analistas que deram avaliações de ações para Vertex Pharmaceuticals Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

428.545 / 498.65Suporte e Resistência

Recent bearish events outweigh bullish events.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.